- Home
- ALVO vs MRUS Comparison
ALVO vs MRUS Comparison
Compare ALVO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- MRUS
- Stock Information
- Founded
- ALVO 2013
- MRUS 2003
- Country
- ALVO Luxembourg
- MRUS Netherlands
- Employees
- ALVO N/A
- MRUS N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- MRUS Health Care
- Exchange
- ALVO Nasdaq
- MRUS Nasdaq
- Market Cap
- ALVO 3.4B
- MRUS 2.7B
- IPO Year
- ALVO N/A
- MRUS 2016
- Fundamental
- Price
- ALVO $8.29
- MRUS $43.06
- Analyst Decision
- ALVO Buy
- MRUS Strong Buy
- Analyst Count
- ALVO 1
- MRUS 13
- Target Price
- ALVO $18.00
- MRUS $86.85
- AVG Volume (30 Days)
- ALVO 162.8K
- MRUS 872.0K
- Earning Date
- ALVO 05-20-2025
- MRUS 05-07-2025
- Dividend Yield
- ALVO N/A
- MRUS N/A
- EPS Growth
- ALVO N/A
- MRUS N/A
- EPS
- ALVO N/A
- MRUS N/A
- Revenue
- ALVO $491,978,000.00
- MRUS $36,133,000.00
- Revenue This Year
- ALVO $33.92
- MRUS $26.81
- Revenue Next Year
- ALVO $45.74
- MRUS $23.85
- P/E Ratio
- ALVO N/A
- MRUS N/A
- Revenue Growth
- ALVO 426.85
- MRUS N/A
- 52 Week Low
- ALVO $7.35
- MRUS $33.19
- 52 Week High
- ALVO $14.76
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- ALVO 32.92
- MRUS 51.15
- Support Level
- ALVO $8.25
- MRUS $33.19
- Resistance Level
- ALVO $8.98
- MRUS $43.46
- Average True Range (ATR)
- ALVO 0.55
- MRUS 3.53
- MACD
- ALVO -0.01
- MRUS 0.34
- Stochastic Oscillator
- ALVO 36.86
- MRUS 80.53
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.